Literature DB >> 19778560

Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice.

Yumiko Mizuno1, Tomoyuki Naoi, Makiya Nishikawa, Sakulrat Rattanakiat, Nobuko Hamaguchi, Mitsuru Hashida, Yoshinobu Takakura.   

Abstract

To achieve delivery of doxorubicin (DXR), a very commonly used anticancer agent, to tumor tissues, it was intercalated to plasmid DNA to obtain a plasmid DNA/DXR complex. The cytotoxic effects of DXR, DNA and their complex were examined in colon26/Luc cells, a murine adenocarcinoma clone stably expressing firefly luciferase, co-cultured with RAW264.7 murine macrophage-like cells. Both CpG motif-containing plasmid DNA (CpG plasmid DNA) and DXR significantly inhibited the proliferation of colon26/Luc cells, but their complex was the most effective among those examined. Non-CpG plasmid DNA was less effective than the CpG plasmid DNA. When injected into mice bearing hepatic metastases of colon26/Luc cells, the CpG plasmid DNA/DXR complex produced a significant level of IL-12 in the serum and liver. The amount of DXR delivered to tumor tissues in the liver was greater when DXR was injected as a CpG plasmid DNA/DXR complex than as free DXR. The CpG plasmid DNA/DXR complex effectively inhibited the proliferation of colon26/Luc cells in the liver compared with free DXR, CpG plasmid DNA, or non-CpG plasmid DNA/DXR complex. These results indicate that CpG plasmid DNA is an effective polymer that inhibits tumor growth by delivering both a proinflammatory signal and anticancer agent to tumor tissues. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19778560     DOI: 10.1016/j.jconrel.2009.09.014

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  8 in total

1.  Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.

Authors:  Amani Makkouk; Vijaya B Joshi; Amaraporn Wongrakpanich; Caitlin D Lemke; Brett P Gross; Aliasger K Salem; George J Weiner
Journal:  AAPS J       Date:  2014-10-18       Impact factor: 4.009

Review 2.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.

Authors:  Xiaopin Duan; Christina Chan; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-15       Impact factor: 15.336

3.  X-shaped DNA potentiates therapeutic efficacy in colitis-associated colon cancer through dual activation of TLR9 and inflammasomes.

Authors:  Jung Eun Koo; Seung Won Shin; Soong Ho Um; Joo Young Lee
Journal:  Mol Cancer       Date:  2015-05-15       Impact factor: 27.401

4.  Interaction between DNA and Drugs Having Protonable Basic Groups: Characterization through Affinity Constants, Drug Release Kinetics, and Conformational Changes.

Authors:  Liliana P Alarcón; Yolima Baena; Rubén H Manzo
Journal:  Sci Pharm       Date:  2017-01-04

5.  Homotypic Cancer Cell Membranes Camouflaged Nanoparticles for Targeting Drug Delivery and Enhanced Chemo-Photothermal Therapy of Glioma.

Authors:  Yajing Ren; Chenlin Miao; Liang Tang; Yuxiang Liu; Pinyue Ni; Yan Gong; Hui Li; Fuxue Chen; Shini Feng
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-27

6.  Organosilane and Polyethylene Glycol Functionalized Magnetic Mesoporous Silica Nanoparticles as Carriers for CpG Immunotherapy In Vitro and In Vivo.

Authors:  Hengrui Zheng; Songsong Wen; Yang Zhang; Zhenliang Sun
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

7.  Folate-conjugated boron nitride nanospheres for targeted delivery of anticancer drugs.

Authors:  Shini Feng; Huijie Zhang; Ting Yan; Dandi Huang; Chunyi Zhi; Hideki Nakanishi; Xiao-Dong Gao
Journal:  Int J Nanomedicine       Date:  2016-09-12

8.  Evaluation of cell surface reactive immuno-adjuvant in combination with immunogenic cell death inducing drug for in situ chemo-immunotherapy.

Authors:  Adam A Walters; Julie Tzu-Wen Wang; Khuloud T Al-Jamal
Journal:  J Control Release       Date:  2020-03-31       Impact factor: 9.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.